Better Buy in 2026: UnitedHealth Group or Eli Lilly?

UnitedHealth Group has tumbled roughly 35% year-to-date amid the public ousting of its insurance CEO, ongoing investigations into alleged billing fraud, unexpectedly high Medicare costs and management actions to raise premiums that could shed up to 1 million Medicare Advantage members; UNH trades at about 21x forward earnings with analysts penciling in roughly 9–10% annualized earnings growth over the next 3–5 years. Eli Lilly has gained roughly 35% year-to-date, reported ~54% year-over-year revenue growth in Q3, and is positioned to benefit from a weight-loss market that forecasters project could expand from $15bn to $150bn over a decade; LLY trades near 45x forward earnings with analysts forecasting ~37% annualized earnings growth and a late-stage pipeline including oral orforglipron and injectable retatrutide. Given Lilly’s momentum and product pipeline versus UnitedHealth’s regulatory, cost and membership risks, the article argues Lilly is the more attractive buy into 2026.

Analysis

Contrarian angles: The market may have over‑punished UNH — if management limits member loss to <300k and guidance reacceleration proves real, a 20–30% rebound is plausible (reversion to ~17x forward P/E). Conversely, consensus may underprice medium‑term political risk to LLY: a policy shock that trims GLP‑1 net prices by 20–40% would compress EY by multiples. Historical parallels include pricing shocks in insulin and HCV drugs where durable demand survived price pressure but margins re‑rated; unintended consequence: insurer premium hikes could accelerate employer/consumer backlash and regulatory intervention, shortening the runway for premium increases.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in LLY via an 12–24 month call‑spread (buy 18‑month calls and sell higher strike calls) to capture expected 30–100% upside from share gains and product launches while capping premium; size to limit max premium loss to 1% portfolio and reassess after 2026 phase‑3 readouts or on >15% adverse price action.
• Initiate a 1–1.5% tactical hedge against UNH: buy 9–12 month puts (or put spreads) sized to cover 1–2% equity exposure to protect vs DOJ/legal headline risk or a further ~15–25% downside; trim hedge if UNH confirms <300k MA member loss and reinstates positive EPS guidance.
• Implement a 1–2% pair trade long LLY / short NVO (1:1 notional) for 12–18 months to express Lilly share‑gains thesis while neutralizing broad GLP‑1 category risk; unwind if regulatory guidance on pricing is issued reducing net prices by >20%.
• Reduce managed‑care exposure by ~20–30% of current weight over next 30 days (sell UNH and peers) and redeploy into pharma/biotech winners (LLY and 1–2 high‑quality medtech names); buy corporate credit protection on top insurers if 5y IG spreads widen by >30bp as a tactical hedge.